Raza Ahmad, Yen Meng-Chi, Anuraga Gangga, Shahzadi Iram, Mazhar Muhammad Waqar, Ta Hoang Dang Khoa, Xuan Do Thi Minh, Dey Sanskriti, Kumar Sachin, Santoso Adrian Wangsawijaya, William Bianca Tobias, Wang Chih-Yang
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Department of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Cancers (Basel). 2023 Oct 23;15(20):5112. doi: 10.3390/cancers15205112.
Glioblastoma multiforme (GBM) is one of the most aggressive cancers with a low overall survival rate. The treatment of GBM is challenging due to the presence of the blood-brain barrier (BBB), which hinders drug delivery. Invasive procedures alone are not effective at completely removing such tumors. Hence, identifying the crucial pathways and biomarkers for the treatment of GBM is of prime importance. We conducted this study to identify the pathways associated with GBM. We used The Cancer Genome Atlas (TCGA) GBM genomic dataset to identify differentially expressed genes (DEGs). We investigated the prognostic values of the guanine nucleotide-binding protein G(i) alpha subunit () family of genes in GBM using a Chinese Glioma Genome Atlas (CGGA) dataset. Within this dataset, we observed the association in the tumor microenvironment between the gene expression of GNAI subunit 3 () and a poor prognosis. MetaCore and gene ontology (GO) analyses were conducted to explore the role of in co-expressed genes and associated signaling pathways using a transcript analysis. Notable pathways included "Cytoskeleton remodeling regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases" and "Immune response B cell antigen receptor (BCR) pathway". A single-cell analysis was used to assess GNAI3 expression in GBM. The results demonstrated that family genes, specifically , were significantly associated with carcinogenesis and malignancy in GBM patients. Our findings suggest that the gene holds potential as a prognostic biomarker for GBM.
多形性胶质母细胞瘤(GBM)是最具侵袭性的癌症之一,总体生存率较低。由于血脑屏障(BBB)的存在,GBM的治疗具有挑战性,血脑屏障会阻碍药物递送。仅靠侵入性手术并不能有效完全切除此类肿瘤。因此,确定治疗GBM的关键途径和生物标志物至关重要。我们开展这项研究以确定与GBM相关的途径。我们使用癌症基因组图谱(TCGA)的GBM基因组数据集来鉴定差异表达基因(DEG)。我们使用中国胶质瘤基因组图谱(CGGA)数据集研究了鸟嘌呤核苷酸结合蛋白G(i)α亚基()基因家族在GBM中的预后价值。在该数据集中,我们观察到GNAI亚基3()的基因表达与肿瘤微环境中的不良预后之间存在关联。使用转录本分析进行MetaCore和基因本体(GO)分析,以探索在共表达基因和相关信号通路中的作用。显著的途径包括“Rho GTPases的激酶效应器对肌动蛋白细胞骨架组织的细胞骨架重塑调节”和“免疫反应B细胞抗原受体(BCR)途径”。使用单细胞分析评估GBM中GNAI3的表达。结果表明,家族基因,特别是,与GBM患者的致癌作用和恶性程度显著相关。我们的研究结果表明,基因具有作为GBM预后生物标志物的潜力。